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Abstract  
G-Protein coupled receptors (GPCRs) activate intracellular signalling pathways by coupling to 
heterotrimeric G-proteins that control many physiological processes including blood pressure 
homeostasis. The Regulator of G-Protein Signalling-1 (RGS1) controls the magnitude and duration of 
downstream GPCR signalling by acting as a GTPase-activating protein for specific Gα-proteins. RGS1 
has contrasting roles in haematopoietic and non-haematopoietic cells. Rgs1
-/-
ApoE
-/-
 mice are protected 
from Angiotensin II (Ang II)-induced aortic aneurysm rupture. Conversely, Ang II treatment increases 
systolic blood pressure to a greater extent in Rgs1
-/-
ApoE
-/- 
mice than ApoE
-/-
 mice, independent of its role 
in myeloid cells. However the precise role of RGS1 in hypertension and vascular-derived cells remains 
unknown. We determined the effects of Rgs1 deletion on vascular function in ApoE
-/-
 mice. Rgs1 deletion 
led to enhanced vasoconstriction in aortas and mesenteric arteries from ApoE
-/-
 mice in response to 
phenylephrine (PE) and U46619 respectively. Rgs1 was shown to have a role in the vasculature, with 
endothelium-dependent vasodilation being impaired, and endothelium-independent dilatation to SNP 
being enhanced in Rgs1
-/-
ApoE
-/- 
mesenteric arteries. To address the downstream signalling pathways in 
vascular smooth muscle cells (VSMCs) in response to Ang II-stimulation, we assessed pErk1/2, pJNK 
and pp38 MAPK activation in VSMCs transiently transfected with Rgs1. pErk1/2 signalling but not pJNK 
and pp38 signalling was impaired in the presence of Rgs1. Furthermore, we demonstrated that the 
enhanced contractile response to PE in Rgs1-/-ApoE-/- aortas was reduced by a MAPK/Erk (MEK) 
inhibitor and an L-type voltage gated calcium channel antagonist, suggesting that Erk1/2 signalling and 
calcium influx are major effectors of Rgs1-mediated vascular contractile responses, respectively . These 
findings indicate RGS1 is a novel regulator of blood pressure homeostasis and highlight RGS1-controlled 
signalling pathways in the vasculature that may be new drug development targets for hypertension. 
 
Abbreviations: Rgs1, Regulator of G-protein Signaling 1; VSMC, vascular smooth muscle cells; Ang II, 
angiotensin II; GPCR, G-protein coupled receptor (GPCR) 
 
Keywords: Rgs1, G-protein signalling, Angiotensin II, smooth muscle cell, vascular function 
 
Introduction 
 
Hypertension is a key risk factor for the development of cardiovascular diseases that can be associated 
with increased G protein-coupled receptor (GPCR) signalling. Vasoactive substances that activate GPCRs 
can regulate blood pressure homeostasis by effecting vessel tone acutely. However, longer term changes 
in systemic pressure and cardiac output leading to vascular dysfunction can result in clinical 
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complications, indicating that tight regulation of GPCR signalling pathways is required to control blood 
pressure [1]. Many physiologically important vasoactive substances such as angiotensin II (Ang II), 
noradrenaline, acetylcholine (ACh) signal through multiple GPCRs that couple to the heterotrimeric G-
protein families of the Gαq and Gαi subunits [2]. Vascular smooth muscle cells (VSMCs) are responsible 
for the contractile and dilatory activity of the vessel wall and thereby modulate peripheral resistance [3]. 
In SMCs, both Ang II and noradrenaline mediate vasoconstriction by activation of Gαq coupled receptors. 
Signalling by Gαq coupled receptor signalling activates several intracellular pathways 
including  diacylglycerol (DAG) and inositol 1,4,5-trisphosphate (IP3), resulting in activation of protein 
kinase C (PKC) and calcium release from intracellular stores, respectively  [4]. Calcium entry across the 
plasma membrane and release from intracellular stores consequently leads to myosin light chain (MLC) 
phosphorylation, activation and ultimately vasoconstriction. 
 
Regulator of G-Protein Signalling (RGS) proteins can modulate G-protein signalling by acting as 
GTPase-activating proteins (GAPs) by accelerating the intrinsic GTPase activity of the Gα subunit 
leading to reformation and inactivation of the heterotrimer [5]. By promoting G-protein inactivation, the 
intracellular response to repeated ligand stimulation is down regulated. We have previously shown that 
RGS1 has a critical role in regulating Ang II mediated aortic aneurysm rupture in ApoE
-/-
 mice through 
attenuation of Gαi chemokine receptor signalling in leukocytes [6]. Rgs1 expression is up-regulated in 
activated inflammatory cells where it functions to inhibit migration, thus promoting the accumulation of 
leukocytes during inflammation. Furthermore, there is indication that RGS1 is involved in Ang II-
mediated blood pressure control via Gαq signalling, independent of its role in myeloid cells and aneurysm 
formation. Other RGS proteins have been implicated in blood pressure control [1], however, to date, the 
role of RGS1 in non-haematopoetic cells and as a regulator of vascular tone has not been explored. 
Understanding the mechanisms that underlie G-protein signalling pathways in blood pressure homeostasis 
may provide new therapeutic targets for hypertension. 
 
To identify physiological mechanisms by which RGS1 regulates blood pressure, we investigated the role 
of Rgs1 in vessel wall activation, and the effect of Rgs1 deletion on vascular function in the conduit and 
resistance vasculature. We used Rgs1
-/-
 mice on an ApoE
-/-
 background, as hyperlipidemia is a common 
co-morbidity with hypertension. Our findings provide the first evidence indicating that RGS1 mediates 
blood pressure by promoting relaxation of the resistance vasculature through its ability to attenuate 
vasoconstrictor-induced signalling. 
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Methods 
Mice 
The generation of Rgs1
-/-
 mice has been previously described [7]. Rgs1
-/-
 mice were crossed onto an ApoE
-
/-
 background (Charles River, UK) to generate matched litters of Rgs1
-/-
ApoE
-/-
 and ApoE
-/-
 mice. Mice 
were housed in individually ventilated cages with 12 h light/dark cycle and controlled temperature (20°C 
- 22°C). Standard chow (B & K Universal Ltd, UK) and water were available ad libitum. All animal 
studies were conducted with ethical approval from the Local Ethical Review Committee and in 
accordance with the UK Home Office Animals (Scientific Procedures) Act 1986. For bone marrow 
transplantation studies, ten-week-old male mice received a lethal dose of whole-body irradiation (2 × 
5 Gy) followed by an i.v. injection of 5 × 106 bone marrow cells from male Rgs1-/-ApoE-/- and ApoE-/- 
mice. 
 
Quantitative real time RT-PCR 
Total RNA was isolated using RNeasy kits (Qiagen, UK) and reverse transcribed to cDNA using 
SuperScript II Reverse Transcriptase (Invitrogen, UK). Quantitative real-time PCR was performed with 
10-50 ng of cDNA on an iCycler IQ real time detection system (Bio-Rad Laboratories Ltd, UK). Gene 
expression was determined using TaqMan Gene Expression Assays (Applied Biosystems, UK) relative to 
the level of the house keeping genes -actin for mouse, and GAPDH for human using real time RT-PCR. 
Relative quantitation of gene expression was performed using the comparative Ct method (ΔΔCt).  
 
Primary cell isolation, culture and cell line transfections 
Primary cells and whole thoracic aortas were obtained from 16-week-old ApoE
-/-
 and Rgs1
-/-
ApoE
-/-
 mice. 
Primary endothelial cells were isolated from PBS perfused lung tissue.  Lungs were finely minced and 
digested in an enzyme solution of DMEM containing 0.18 U/ml Liberase Blendzyme 3 (130 μl; Roche, 
UK) and 0.1 mg/ml DNase I (100 μl; Roche, UK) for 1 hour at 37°C with gentle agitation. Purification of 
endothelial cells was performed by magnetic cell sorting (Miltenyi Biotec, UK) by positive selection 
using anti-CD31 microbeads (Miltenyi Biotec, UK). Primary VSMCs were isolated by the aortic explant 
method. Aortas were cut into small segments following endothelial cell denudation and adhered onto 2% 
gelatin coated wells and cultured in DMEM complete growth media for 2 weeks. Outgrowing VSMCs 
from explants of aortic tissue were harvested using Trypsin/EDTA and pelleted for RNA.  
 
The murine vascular aortic smooth muscle cell line, MOVAS (ATCC CRL-2797) were transiently 
transfected at 50% confluency with plasmid expressing Myc-DDK (FLAG) tagged murine Rgs1 
(Origene) or an empty mammalian expression vector (pcDNA3.1) using FuGENE HD (Roche) in serum 
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free DMEM media. Transfections were performed at 3:1 ratio of FuGENE HD to 1 μg DNA. To check 
for transfection efficiency, in parallel experiments, intracellular staining and flow cytometry was 
performed for the FLAG tag using an anti-FLAG FITC antibody (Sigma). For staining of intracellular 
FLAG expression, cells were washed, fixed in 2% PFA (Life Technologies,) then permeabilised by 
incubation with Cytofix/Cytoperm then washed in PermWash (BD Biosciences). Cells were then 
incubated in Fc block and antibody stained for FLAG. Data were acquired using a CyAn Analyser flow 
cytometer (Beckman Coulter, UK) and then analysed using Summit (Dako, UK) and FlowJo (Tree Star 
Inc, USA) software. Between 48 to 72 hours, the time point at which the signalling assays were 
performed, 72% of all cells were FLAG tag positive, indicating RGS1 expression in transfected cells 
(Supplementary Figure 1).  
 
Measurement of pErk, pJNK and pp38 MAPK. 
MOVAS cells were seeded in 24-well plates and transfected with pcDNA3.1 or Rgs1, 24 hours prior to 
performance of assays. Transfected cells were incubated in serum-free media 12 hours prior to treatment 
of cells with 1 uM of Angiotensin II over 30 minutes. Cells were then lysed in Surefire lysis buffer, and 
AlphaScreen Surefire pERK, pJNK, pp38, total ERK and GAPDH assays (PerkinElmer, Beaconsfield, 
UK) measuring phosphorylated and total proteins were performed, as described [8]. The fluorescence 
signal in both assays was measured using the PHERAstar FS microplate reader (BMG Labtech). The ratio 
of phosphorylated ERK (pERK) to total ERK, pJNK and pp38 to GAPDH was measured at each time 
point. All assay conditions were performed in four biological replicates on two independent occasions.  
 
Angiotensin II infusion and unconscious arterial pressure monitoring 
16 week old chimeric male mice were anaesthetized with isoflurane by inhalation and osmotic mini 
pumps (Alza Corp, USA) delivering Ang II (3 mg kg−1 per day; Sigma-Aldrich) for 14 days were 
implanted subcutaneously. At day 14, mean arterial blood pressure and heart rate was measured by 
catheterizing the right common carotid artery with a Millar 1.4 French blood pressure probe and 
transducer (Millar Instruments Inc., Houston, TX) coupled to a Powerlab/4sp data acquisition system 
(ADInstruments Pty Ltd., New Castle, Australia) and passing the probe into the ascending aorta.  After 
15min equilibrium period blood pressure was measured for 5 min and the average recordings for this time 
taken.    
 
Isometric tension vasomotor studies 
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Vasomotor function was analysed using isometric tension studies in a wire myograph (Multi-Myograph 
610M, Danish Myo Technology, Denmark). Briefly, mice were culled by overdose of inhaled isoflurane 
and vascular rings were isolated from the thoracic aorta or mesenteric arcades. The aortic rings or 2
nd
 
order mesenteric arteries (2 mm) were mounted on a wire myograph containing 5 ml of Krebs–Henseleit 
buffer (KHB [in mmol/l]: NaCl 120, KCl 4.7, MgSO4 1.2, KH2PO4 1.2, CaCl2 2.5, NaHCO3 25, glucose 
5.5) at 37 °C, gassed with 95% O2/5% CO2. After allowing vessels to equilibrate for 30 min, the optimal 
tension was set (equivalent to 100 mm Hg). The vessel viability was tested using 60 mM KCl. 
Concentration–response contraction curves were established using cumulative half-log concentrations of 
phenylephrine, U46619 and Ang II. Acetylcholine and SLIGRL were used to stimulate endothelium-
dependent vasodilatations in increasing cumulative concentrations. Responses were expressed as a 
percentage of the pre-constricted tension. The NO donor sodium nitroprusside (SNP) was used to test 
endothelium-independent smooth muscle relaxation in the presence of 100 µM L-NAME. The MEK 
inhibitor, PD98059 (10 uM) and the L-type voltage gated calcium channel antagonist, Nifedipine (50 nM) 
were used to block PE induced vasoconstriction in aortas. All pharmacological drugs were pre-incubated 
at least 20 min before the dose–response curves were determined. All drugs used were purchased from 
Sigma Aldrich. 
 
Statistical Analysis 
Between group comparisons of normally distributed measurements were assessed by Student's t-test. One-
way AVOVA was used to compare more than two data groups and Dunnett’s post-test was used to 
compare each group to a control (untreated) group. Two-way ANOVA was used to compare multiple data 
groups affected by two independent variables, with a Bonferroni correction to compare groups with each 
other. Differences were considered statistically significant at P<0.05. 
 
Results  
 
Rgs1 deficiency in non-haematopoietic cells results in Angiotensin II- induced hypertension in 
ApoE
-/- 
mice 
We had previously shown that Ang II infusion for 14 days resulted in a significant increase in blood 
pressure in Rgs1
-/-
ApoE
-/-
 mice. We first aimed to establish if the increase in blood pressure that was 
observed at the slow pressor dose used previously, was still present at a higher pressor dose of Ang II. 
Invasive blood pressure recordings in unconscious mice were performed after 14 days of Ang II infusion 
(3mg/kg/day). Consistent with our previous study [6], we found significant differences in systolic blood 
pressure between ApoE
-/-
 mice transplanted with ApoE
-/-
 bone marrow and Rgs1
-/-
ApoE
-/-
 mice 
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transplanted with Rgs1
-/-
ApoE
-/-
 bone marrow (101.3 ± 3.944 mm Hg versus 137.5 ± 3.056 mm Hg; 
P<0.0001; Figure 1A). In addition an increase in systolic blood pressure was also observed in Rgs1
-/-
ApoE
-/-
 mice transplanted with ApoE
-/-
 bone marrow  (101.3 ± 3.944 mm Hg versus 132.4 ± 5.218 
mm Hg; P=0.0002; Figure 1A,D), indicating that the increase in systolic blood pressure was not due to a 
contribution of haematopoietic cells as described in previous studies [9]. In line with the changes 
observed in systolic blood pressure, a significant increase in diastolic blood pressure between ApoE
-/-
 
mice transplanted with ApoE
-/-
 bone marrow and Rgs1
-/-
ApoE
-/-
 mice transplanted with ApoE
-/-
 bone 
marrow was significantly altered (65.18 ± 3.462 mm Hg versus 85.21 ± 2.652 mm Hg; Figure 1B; 
P=0.0002). Heart rate was similar between ApoE
-/-
 and Rgs1
-/-
ApoE
-/-
 mice (450.2 ± 25.29 beats/min 
versus 470.2 ± 13.06 beats/min; Figure 1C). 
 
Rgs1 mRNA down-regulation in response to prolonged Ang II stimulation. 
We next examined the possible regulation of Rgs1 to the effects of Ang II-mediated AT1 receptor 
activation in the vasculature. To assess this we measured the expression of Rgs1 following the 
administration of Ang II in vivo and in vitro. We first measured the expression of Rgs1 mRNA in thoracic 
aortas from ApoE
-/-
 mice implanted with saline and Ang II for 5 days and found Rgs1 mRNA expression 
was significantly reduced in aortas from Ang II-treated ApoE
-/-
 mice compared to saline treated mice 
(Figure 2A). We next measured expression in isolated and cultured primary endothelial and VSMCs 
stimulated with Ang II in vitro (Figure 2B) and found Rgs1 expression was reduced with stimulation.  
These findings indicate RGS1 is a likely candidate for negative regulation of the Gαq proteins coupled to 
the Ang II type 1 receptor in the vascular wall, and endothelial and VSMCs.  
 
 
Rgs1 deletion leads to enhanced vasoconstriction in aortas and mesenteric arteries from ApoE
-/-
 
mice 
VSMCs express a number of GPCRs, such as adrenergic receptors that are essential in mediating 
sympathetic signalling. Alpha-adrenergic receptors are Gαq coupled and induce phospholipase C (PLC) 
activation and a subsequent increase in intracellular calcium which is required for the initiation of calcium 
dependant SMC contraction, and in vessels; calcium dependant vasoconstriction.  
 
To test the effect of RGS1 in Gαq vasomotor function, we determined vascular reactivity in conduit 
vessels from ApoE
-/-
 and Rgs1
-/-
ApoE
-/-
 mice. No difference was detected between the contraction 
response to 60 mmol∙L-1 KCl in ApoE-/- (7.872 ± 0.59 mN∙mm-1) and Rgs1-/-ApoE-/- aortas (7.561± 0.30 
mN∙mm-1) (Figure 3A). Receptor-mediated vasoconstrictions to α-adrenergic agonist, phenylephrine (PE), 
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were significantly enhanced in Rgs1
-/-
ApoE
-/-
 aortas compared to ApoE
-/-
 controls (Figure 3B). In contrast 
to PE, receptor-mediated vasoconstrictions to AT1 agonist, Ang II had very little effect on 
vasoconstrictions in aortas from both ApoE
-/-
 and Rgs1
-/-
ApoE
-/-
 mice (Figure 3C). Additionally, 
endothelium-dependent vasodilatation was impaired in Rgs1
-/-
ApoE
-/-
 aortas compared to ApoE
-/-
 control 
aortas (Figure 3D), but there was no difference in endothelium-independent vasodilatation to SNP 
between the genotypes (Figure 3E). To address the finding that the enhanced contractile response to 
vasoconstrictors in Rgs1-/-ApoE-/- aortas was in part due to MAPK signalling we assessed 
vasoconstriction to PE in the presence of a MAPK/Erk (MEK) inhibitor and found the response was 
blunted (Figure 3F). Smooth muscle contraction is also dependent on calcium signalling, therefore we 
assessed the response of Rgs1-/-ApoE-/- aortas to PE vasoconstriction in the presence of a L-type voltage 
gated calcium channel antagonist. We observed that the enhanced contractile response to PE in Rgs1-/-
ApoE-/- aortas was reduced by an L-type voltage gated calcium channel antagonist to the same extent as 
that of ApoE-/- aortas(Figure 3G). These observations indicate that calcium signalling and MAPK 
signalling are major effectors of Rgs1-mediated vascular contractile responses, which are known to be 
activated downstream of the Gaq receptor signalling. 
 
To further investigate the relationships between blood pressure and changes in the resistance vasculature, 
mesenteric arteries from ApoE
-/-
 and Rgs1
-/-
ApoE
-/-
 mice were isolated and the contractile response to 
vasoconstrictors and vasodilators were determined. In Rgs1
-/-
ApoE
-/-
 mesenteric arteries, receptor-
mediated vasoconstrictions to thromboxane A2 receptor agonist, U46619, were significantly enhanced 
compared to ApoE
-/-
 controls (Figure 4A). In addition, receptor-mediated vasoconstrictions to AT1 
receptor agonist, Ang II were also markedly enhanced in Rgs1
-/-
ApoE
-/-
 compared to ApoE
-/-
 (Figure 4B). 
Endothelium-dependent vasodilatations in response to ACh and the proteinase-activated receptor 2 
agonist, SLIGRL were both significantly impaired in Rgs1
-/-
ApoE
-/-
 mesenteric arteries when compared 
with that in ApoE
-/-
 mesenteric arteries (Figure 4C, 4D). The vasodilatory response to ACh were 
normalised in the presence of non-selective nitric oxide synthase inhibitor (L-NAME) and showed no 
change between groups (Figure 4E). Furthermore, endothelium-independent vasodilatation to SNP was 
enhanced in Rgs1
-/-
ApoE
-/-
 mesenteric arteries when compared to mesenteric arteries from ApoE
-/-
 mice 
(Figure 4F), indicating the impairment of vasodilatation in Rgs1
-/-
ApoE
-/-
 mesenteric arteries was due to 
the alteration of vascular smooth muscle sensitivity. Together, these findings indicate that Rgs1 regulates 
blood pressure in resistance arteries. 
 
Rgs1 attenuates Ang II stimulated Erk1/2 phosphorylation in VSMCs 
Ang II signals through AT1 receptors (AT1R), that are implicated in AngII-induced vasoconstriction. 
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Following activation of the receptor, Gα and Gβγ subunits dissociate, activating downstream signalling 
cascades. Extracellular regulated kinases 1 and 2 are ubiquitously utilized proteins for examining 
vasoactive signalling due to their role in the propagation of ligand activated signalling through GPCRs 
[10].  Specifically, this signalling has been connected to Gαq and Gαi signalling, and can lead to a 
number of intracellular downstream effects ranging from migration and adhesion to proliferation. ERK is 
phosphorylated and activated by at least three downstream AT1R signalling pathways, including the 
protein kinase C (PKC)-dependent pathway, the β-arrestin-dependent pathway, and the epidermal growth 
factor receptor (EGFR) transactivation pathway [11]. To assess the role of RGS1 in the Ang II-stimulated 
activation of the MAPK signalling pathway, we assessed the levels of phosphorylated Erk1/2 protein and 
other known kinases induced by Ang II, using transient transfections of Rgs1 in the murine vascular 
smooth muscle cell line (MOVAS). We found that RGS1 reduced pERK signalling following 
Angiotensin II stimulation over a 30 minute time course (Figure 5A), but not pJNK or pp38 signalling 
(Figure 5B,C). Furthermore, we also found pERK levels at 10, 15 and 20 minutes were below baseline. 
The mechanisms underlying the increased contraction in Rgs1 deficient vessels and Ang II-mediated 
hypertension in Rgs1-/-ApoE-/- mice are likely to involve different signalling cascades involving both 
MAPK signalling and calcium influx, which are known to be activated downstream of the alpha-
adrenergic receptor and AT1R. Numerous signalling pathways in response to Ang II are mediated by 
reactive oxygen species (ROS) and oxidative stress underlies major vascular diseases including 
atherosclerosis and abdominal aortic aneurysm.  Ang II-induced ROS  including superoxide and hydrogen 
peroxide, can influence vascular tone, remodelling and induce hypertension by vascular constriction, as 
well as nitric oxide inactivation [12]. We assessed hydrogen peroxide released from VSMC transfected 
with Rgs1, stimulated with Ang II for 12 hours. We observed no differences in basal hydrogen peroxide 
production, and after Ang II stimulation in supernatants from VSMCs transfected with Rgs1 (data not 
shown).  
 
 
Discussion  
 
The modulation of blood pressure by GPCRs is essential in the maintenance of normal cardiovascular 
function, which when compromised can result in vascular dysfunction and hypertension, a risk factor for 
peripheral atherosclerosis, renal failure, myocardial infarction and stroke. Furthermore, GPCR activity 
has been a target by many drugs to treat hypertension, including AT1 receptor and β- adrenergic receptor 
antagonists [13]. To date, three members of the RGS protein family; RGS2, RGS4 and RGS5 have been 
linked to blood pressure maintenance [1]. Our results provide new insights into the role of RGS1 as an 
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additional regulator of vascular tone and blood pressure. In this study we have shown that loss of Rgs1 on 
the hyperlipidemic ApoE-/- background resulted in an enhanced arterial constrictor response in both 
conduit and resistance arteries. In addition, the loss of Rgs1 resulted in endothelial cell dysfunction with a 
blunted endothelial dilator response, which was apparent despite an increase in VSMC sensitivity to NO.  
Hypertension can be associated with the dysfunction of the renin angiotensin system (RAS) [14]. 
Angiotensin II (Ang II), a primary effector of the RAS, is produced both systemically and locally in the 
vessel wall [15] with its effects mediated by the Angiotensin type I receptors. We show that loss of Rgs1 
leads to an increased sensitivity to chronic treatment with Ang II resulting in a significant increase in both 
systolic and diastolic blood pressure. Previous studies have shown a role of haematopoietic cells, 
specifically T cells in the hypertensive response to Ang II [9]. Using the rag1-/- mice lacking T and B 
cells and adoptive transfer, Guzik et al, demonstrated hypertension was associated with T-cell infiltration 
in perivascular tissue, oxidative stress and impairment in endothelial-dependent vasodilatation. As we and 
others have previously shown, RGS1 is highly expressed in leukocytes and plays a critical role in myeloid 
cell [6] and lymphoid cell [16] retention in inflammatory disease pathogenesis. Hence in order to 
ascertain if the increased blood pressure response in Rgs1
-/-
ApoE
-/-
 Ang II treated mice was in part due to 
a contribution of RGS1 from leukocytes we generated bone marrow chimeras. The increased blood 
pressure response was only observed in Rgs1
-/-
ApoE
-/-
 receiving Rgs1
-/-
ApoE
-/-
 or ApoE
-/-
 bone marrow, 
strongly implicating loss of Rgs1 in the vessel wall, results in the enhanced hypertensive response to Ang 
II. In our previous study, we examined the T-cell and B-cell phenotype of Rgs1
-/-
ApoE
-/-
 mice and found 
no significant alterations, suggesting RGS1 in lymphocytes in the context of atherosclerosis and Ang II 
induced AAA has a less significant role to that in myeloid cells in vascular inflammation. We did not 
observe any differences in heart rate between Rgs1
-/-
ApoE
-/-
 mice and ApoE
-/-
 mice despite the observed 
increase in blood pressure. Previous studies have demonstrated that Ang II modifies the barrow receptor 
reflex either by decreasing sensitivity, or by resetting the reflex to a higher value [17, 18], and this central 
effect most likely explains the absence of reflex bradycardia. Other RGS proteins have been implicated in 
the aetiology of hypertension. There is strong evidence linking Rgs2 and hypertension in humans. Genetic 
studies have identified Rgs2 single nucleotide polymorphisms (SNPs) in hypertension cohorts from 
several regions around the world[19]. Rgs1 also resides in the same locus of chromosome 1q, which 
harbours multiple susceptibility genes that affect blood pressure levels [20, 21], indicating potential SNPs 
in Rgs1 could also affect hypertension in humans. Previous studies have shown that Rgs2
-/-
 mice are 
hypertensive at baseline and following Ang II infusion [22]. RGS2 is required for cGMP-mediated 
inhibition of vasoconstrictor-triggered Ca2+ signalling [23, 24].  
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The loss of RGS1 resulted in a significant increase in the contractile response to phenylephrine in the 
aorta, and to Ang II and the thromboxane mimetic U46619 in resistance arteries.  It is unlikely that the 
enhanced constrictor response observed is due to an alteration in remodelling in these vessels as there was 
no difference in the contractile response to KCL. The enhanced contraction to PE was blunted in both 
Rgs1-/-ApoE-/- mice and ApoE-/- aortas following addition of MEK inhibitor and an L-type voltage 
gated calcium channel antagonist. Contraction is maintained by calcium sensitisation of the contractile 
proteins via several signalling pathways. Phenylephrine, Ang II [25] and U46619 [26] act via Gaq 
signalling to cause Ca2+ dependent phosphorylation of MLC via activation of phospholipase C. In 
addition these agonists also activate G12/13 signalling which increases calcium sensitivity by Rho kinase-
mediated inhibition of MLC phosphorylation. Erk1/2 can potentiate contraction via caldesmon 
phosphorylation, leading to separation from actin and thereby increasing the binding of actin and myosin 
[27]. Rgs1 is an upstream effector of many signalling pathways including the MAPK pathway, acting at 
the level of the Ga protein to cause signal termination. Previous in vitro studies have shown that RGS1 is 
a Gai and Gαq GTPase-activating protein and a potential G12 effector antagonist [28]. It is likely that the 
enhanced constrictor response observed in the aorta and mesenteric arteries of Rgs1
-/-
ApoE
-/-
 mice is due 
to loss of RGS1 inactivation of Gq and G12/13 and loss of signal termination. Furthermore, receptor 
stimulation by Ang II is followed by a rapid desensitization of the intracellular signal transduction and a 
decrease in cell surface receptor number, which could account for the drop in pErk1/2 levels from 
baseline following Ang II stimulation of VSMCs. In Rgs2
-/-
 mice, the enhanced constrictor response was 
due to loss of the NO mediated upregulation of RGS2 activity, leading to an alteration in balance between 
the constrictor and dilator responses towards a constricted phenotype. It is unlikely that a similar 
mechanism is responsible in our study, as in contrast the Rgs2
-/-
 mice, we observed an enhanced dilatory 
response to the NO donor SNP. The absence of RGS1, effects the regulation of VSMC contraction and 
dilation in response to the agonists tested, but does not rule out the possibility that RGS1 specifically 
regulates other GPCR-mediated pathways that were not tested in this study. In contrast to Rgs1 and Rgs2 
deficient mice being hypertensive, contradictory observations have been found in Rgs5
-/- 
mice. Rgs5
-/- 
mice have been shown to be hypotensive [29] and hypertensive [30]. The mechanism for hypotension is 
thought to occur through inhibition of NO-mediated dilatory signalling. However, in arterial VSMCs, 
RGS5 inhibits Ang II and Endothelin-1-induced intracellular Ca
2+
 transients mediated by Gαi and Gαq 
signalling [31]. These contrasting roles imply that RGS proteins function in a complex system of GPCR 
signal transduction by their selectivity towards specific G-proteins. In line with the findings observed for 
Rgs1 in this study, Rgs2 and Rgs5 mRNA transcripts are also regulated by Ang II in VSMCs [32] and 
aortas from Ang II infused mice [30], respectively.  The in vivo Ang II infusion model indicated Rgs1 
provided negative feedback to Ang II signalling and provided the opportunity to investigate the prolonged 
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Ang II treatment of endothelial cells and VSMCs which showed down-regulation of Rgs1. Together, 
these data suggest that Rgs1, Rgs2 and Rgs5 are functionally important negative regulators of Ang II 
signalling in the vessel wall. 
 
In addition to the alteration in the contractile response, a blunted endothelial dependent dilator response 
was also observed in both aorta and resistance mesenteric arteries from Rgs1
-/-
ApoE
-/-
 mice. Both ACh 
and the PAR-2 agonist SLIGRL act via Gq11 dependent endothelial cell receptors. If RGS1 were coupled 
to these GPCRs then it would be expected that loss of RGS1 would result in an enhanced dilator response. 
In our study, a significant proportion of the dilator response to Ach was inhibited by NOS inhibition, 
indicating that the majority of the dilatory response was due to NOS derived vasodilators. Previous in 
vivo studies have shown that a slow pressor dose of Ang II is associated with a significant increase in 
oxidative stress [33]. The blunted dilatory response observed in Rgs1
-/-
ApoE
-/-
 mice could be due to 
chronic over activation of the Ang II signalling pathway leading to increased reactive oxygen species and 
decreased NO bioavailability. Although we did not observed any differences in hydrogen peroxide 
production in VSMCs stimulated with Ang II, this does not account for possible changes in vascular 
tissue. Interestingly, in contrast to the blunted response to dilation observed with Ach, the dilatory 
response to the PAR-2 agonist SLIGRL did not show a reduction in the maximum dilatory response but 
instead a decreased sensitivity. This difference could be due to the relative potency of these two 
compounds as SLIGRL has been shown to induce a more potent dilatory response compared to Ach [34]. 
However, it could also be due to differences in the relative contribution of vasodilators; SLIGRL has been 
shown to utilize both NOS-cGMP dependent and independent mechanisms [35]. 
In conclusion, our results indicate that RGS1 regulates blood pressure to a significant extent to relax the 
resistance vasculature and attenuate vasoconstrictor signalling in the vasculature. We propose that RGS1 
terminates Ang II signalling through accelerating the inactivation of the Gaq subunit of AT1 receptors 
that can propagate signals via multiple pathways including downstream Erk1/2 signalling pathways and 
intracellular calcium levels, which results in attenuated VSMC contraction. Furthermore, genetic 
impairment of Rgs1 therefore may contribute to the development of hypertension. These findings further 
promote the importance of RGS proteins as potential targets for the treatment of hypertension.  
Specifically, pharmacological agents that up-regulate RGS1 expression or activity in the vessel wall may 
augment the action of vasodilatory agonists and provide a novel means of treating hypertension. 
Acknowledgements 
This work was supported by the British Heart Foundation (RG/10/15/28578), the Wellcome Trust 
(091504/Z/10/Z and 090532/Z/09/Z), the BHF Centre for Research Excellence (RE/13/1/30181) and the 
13 
 
National Institute for Health Research (NIHR) Oxford Biomedical Research Centre. We thank Dr J. Kehrl 
for providing Rgs1
-/-
mice, Dr. Nicola Smart for providing the MOVAS cell line, and Dr. Eileen McNeill 
and Dr. Mark Crabtree for helpful comments and discussions. 
 
Competing financial interests 
The authors declare no competing financial interests. 
 
References 
1. Brinks, H.L. and A.D. Eckhart, Regulation of GPCR signaling in hypertension. Biochim Biophys 
Acta, 2010. 1802(12): p. 1268-75. 
2. Demoliou-Mason, C.D., G-protein-coupled receptors in vascular smooth muscle cells. Biol Signals 
Recept, 1998. 7(2): p. 90-7. 
3. Owens, G.K., Regulation of differentiation of vascular smooth muscle cells. Physiological 
Reviews, 1995. 75: p. 487-517. 
4. Billups, D., et al., Modulation of Gq-protein-coupled inositol trisphosphate and Ca2+ signaling by 
the membrane potential. J Neurosci, 2006. 26(39): p. 9983-95. 
5. Xie, Z., E.C. Chan, and K.M. Druey, R4 Regulator of G Protein Signaling (RGS) Proteins in 
Inflammation and Immunity. AAPS J, 2016. 18(2): p. 294-304. 
6. Patel, J., et al., RGS1 regulates myeloid cell accumulation in atherosclerosis and aortic aneurysm 
rupture through altered chemokine signalling. Nat Commun, 2015. 6. 
7. Moratz, C., et al., Abnormal B-cell responses to chemokines, disturbed plasma cell localization, 
and distorted immune tissue architecture in Rgs1-/- mice. Mol Cell Biol, 2004. 24(13): p. 5767-75. 
8. Gorvin, C.M., et al., Galpha11 mutation in mice causes hypocalcemia rectifiable by calcilytic 
therapy. JCI Insight, 2017. 2(3): p. e91103. 
9. Guzik, T.J., et al., Role of the T cell in the genesis of angiotensin II induced hypertension and 
vascular dysfunction. J. Exp. Med., 2007. 204(10): p. 2449-2460. 
10. Leroy, D., et al., G protein-coupled receptor-mediated ERK1/2 phosphorylation: towards a 
generic sensor of GPCR activation. J Recept Signal Transduct Res, 2007. 27(1): p. 83-97. 
11. Tilley, D.G., Functional relevance of biased signaling at the angiotensin II type 1 receptor. Endocr 
Metab Immune Disord Drug Targets, 2011. 11(2): p. 99-111. 
12. Hitomi, H., H. Kiyomoto, and A. Nishiyama, Angiotensin II and oxidative stress. Curr Opin Cardiol, 
2007. 22(4): p. 311-5. 
13. Insel, P.A., et al., Impact of GPCRs in clinical medicine: monogenic diseases, genetic variants and 
drug targets. Biochim Biophys Acta, 2007. 1768(4): p. 994-1005. 
14. Warren, H.R., et al., Genome-wide association analysis identifies novel blood pressure loci and 
offers biological insights into cardiovascular risk. Nat Genet, 2017. 49(3): p. 403-415. 
15. Nguyen Dinh Cat, A. and R.M. Touyz, Cell signaling of angiotensin II on vascular tone: novel 
mechanisms. Current hypertension reports, 2011. 13(2): p. 122-8. 
16. Gibbons, D.L., et al., Cutting Edge: Regulator of G protein signaling-1 selectively regulates gut T 
cell trafficking and colitic potential. J Immunol, 2011. 187(5): p. 2067-71. 
17. Brooks, V.L., Chronic infusion of angiotensin II resets baroreflex control of heart rate by an 
arterial pressure-independent mechanism. Hypertension, 1995. 26(3): p. 420-4. 
18. Reid, I.A., Interactions between ANG II, sympathetic nervous system, and baroreceptor reflexes in 
regulation of blood pressure. Am J Physiol, 1992. 262(6 Pt 1): p. E763-78. 
14 
 
19. Riddle, E.L., et al., Polymorphisms and haplotypes of the regulator of G protein signaling-2 gene 
in normotensives and hypertensives. Hypertension, 2006. 47(3): p. 415-20. 
20. Ehret, G.B., et al., Follow-up of a major linkage peak on chromosome 1 reveals suggestive QTLs 
associated with essential hypertension: GenNet study. Eur J Hum Genet, 2009. 17(12): p. 1650-7. 
21. Chang, Y.P., et al., Multiple genes for essential-hypertension susceptibility on chromosome 1q. 
Am J Hum Genet, 2007. 80(2): p. 253-64. 
22. Hercule, H.C., et al., Regulator of G protein signalling 2 ameliorates angiotensin II-induced 
hypertension in mice. Experimental physiology, 2007. 92(6): p. 1014-22. 
23. Sun, X., et al., RGS2 is a mediator of nitric oxide action on blood pressure and vasoconstrictor 
signaling. Mol Pharmacol, 2005. 67(3): p. 631-9. 
24. Osei-Owusu, P., et al., Regulation of RGS2 and second messenger signaling in vascular smooth 
muscle cells by cGMP-dependent protein kinase. J Biol Chem, 2007. 282(43): p. 31656-65. 
25. Gohla, A., G. Schultz, and S. Offermanns, Role for G(12)/G(13) in agonist-induced vascular 
smooth muscle cell contraction. Circ Res, 2000. 87(3): p. 221-7. 
26. Offermanns, S., et al., G proteins of the G12 family are activated via thromboxane A2 and 
thrombin receptors in human platelets. Proc Natl Acad Sci U S A, 1994. 91(2): p. 504-8. 
27. Yu, J., et al., The inhibitory effects of isoflurane on protein tyrosine phosphorylation-modulated 
contraction of rat aortic smooth muscle. Anesthesiology, 2004. 101(6): p. 1325-31. 
28. Moratz, C., et al., Regulator of G protein signaling 1 (RGS1) markedly impairs Gi alpha signaling 
responses of B lymphocytes. J Immunol, 2000. 164(4): p. 1829-38. 
29. Nisancioglu, M.H., et al., Generation and characterization of rgs5 mutant mice. Mol Cell Biol, 
2008. 28(7): p. 2324-31. 
30. Holobotovskyy, V., et al., Regulator of G-protein signaling 5 controls blood pressure homeostasis 
and vessel wall remodeling. Circ Res, 2013. 112(5): p. 781-91. 
31. Arnold, C., et al., RGS5 promotes arterial growth during arteriogenesis. EMBO Mol Med, 2014. 
6(8): p. 1075-89. 
32. Grant, S.L., et al., Specific regulation of RGS2 messenger RNA by angiotensin II in cultured 
vascular smooth muscle cells. Mol Pharmacol, 2000. 57(3): p. 460-7. 
33. Kawada, N., et al., A mouse model of angiotensin II slow pressor response: role of oxidative 
stress. J Am Soc Nephrol, 2002. 13(12): p. 2860-8. 
34. Beleznai, T., et al., Enhanced K(+)-channel-mediated endothelium-dependent local and 
conducted dilation of small mesenteric arteries from ApoE(-/-) mice. Cardiovasc Res, 2011. 92(2): 
p. 199-208. 
35. McGuire, J.J., et al., Multiple mechanisms of vascular smooth muscle relaxation by the activation 
of proteinase-activated receptor 2 in mouse mesenteric arterioles. Br J Pharmacol, 2002. 135(1): 
p. 155-69. 
 
 
050
100
150
Recipient
BM donor
WT KO WTKO
WT WTKO KO
***
***
S
y
s
to
lic
 B
lo
o
d
 P
re
s
s
u
re
 (
m
m
H
g
)
0
20
40
60
80
100
Recipient
BM donor
WT KO WTKO
WT WTKO KO
***
***
D
ia
s
to
lic
 B
lo
o
d
 P
re
s
s
u
re
 (
m
m
H
g
)
0
200
400
600
Recipient
BM donor
WT KO WTKO
WT WTKO KO
H
e
a
rt
 r
a
te
 (
B
e
a
ts
/m
in
)
90
110
130
150
WT>WT
KO>KO
WT>KO
KO>WT
0 60
Time (s)
S
y
s
to
lic
 B
lo
o
d
 P
re
s
s
u
re
 (
m
m
H
g
)
Figure 1 
Figure 1: Rgs1-/-ApoE-/- chimeric mice have increased blood pressure responses 
after Ang II infusion for 14 days. Chimeric ApoE−/− and Rgs1−/− ApoE−/− mice were 
infused with Ang II (3 mg kg−1 per day) over 14 days and blood pressure measured at day 
14 in anaesthetized mice using a Millar catheter. (A) Systolic blood pressure (B) Diastolic 
blood pressure (C) Heart rate in Rgs1-/-ApoE-/- and ApoE-/-  chimeric mice.  (D) 
Representative traces of systolic blood pressure in chimeric mice using a Millar catheter 
(***P<0.001; n=10-11 animals per group). WT = ApoE-/- ; KO= Rgs1-/-ApoE-/- 
A B 
C D 
Figure 2 
Figure 2: Rgs1 mRNA is down-regulated following Ang II stimulation. qRT–PCR 
analysis of Rgs1 mRNA in (A) thoracic aortas from ApoE−/− mice following 5 day saline or 
Ang II infusion (0.8mg/kg/day) (B) primary endothelial cells and primary VSMCs 
from ApoE−/− mice stimulated for 24 hours with Ang II (1 uM) in vitro after a 5 day culture 
presented relative to mRNA in unstimulated cells, set as 1 (n=4–7; *P<0.05). 
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Figure 3 
Figure 3: Rgs1-/-ApoE-/- aortas have altered vasoconstrictor and vasodilator responses. 
(A) Maximal contraction of aortas to 45 mmol·L−1 KCl. (B) Vasoconstriction to phenylephrine (PE) 
was enhanced in  Rgs1-/-ApoE-/- aortas when compared with ApoE-/- aortas. (C) Ang II did not 
cause a contractile response of the aorta in either group. (D) Endothelial-dependent vasodilatation to 
acetylcholine (Ach) was altered in  Rgs1-/-ApoE-/- aortas and (E) Endothelium-independent 
vasodilatation in response to sodium nitroprusside (SNP) was unchanged between groups (F) 
Vasoconstriction to PE was abolished in the presence of a MEK inhibitor (10 uM PD98059) in both 
Rgs1-/-ApoE-/- and ApoE-/- aortas. (G) Vasoconstriction to PE was partially blunted in the presence 
of a L-type voltage gated calcium channel antagonist (50 nM Nifedipine) in both Rgs1-/-ApoE-/- and 
ApoE-/- aortas (*P<0.05; A-E; n=6 animals per group F-G n=4 animals per group ).  
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Figure 4 
Figure 4: Altered vasomotor function in isolated 2nd order mesenteric arteries 
from Rgs1-/-ApoE-/- mice. Vasoconstriction in responses to (A) U46619 and (B) Ang 
II was enhanced in 2nd order mesenteric arteries from Rgs1-/-ApoE-/-  mice compared 
to ApoE-/- mice. Endothelium-dependent vasodilatation to (C) acetylcholine (Ach) and 
(D) SLIGRL were impaired in Rgs1-/-ApoE-/- mesenteric arteries. (E) The vasodilatory 
response to ACh were normalised in the presence of non-selective nitric oxide 
synthase inhibitor (100 mM; L-NAME) and showed no change between groups. (F) 
Endothelium-independent vasodilatation to sodium nitroprusside (SNP) was impaired in 
ApoE-/- mesenteric arteries compared to Rgs1-/-ApoE-/- mesenteric arteries 
(*P < 0.05, **P < 0.01; n = 6 to 9 animals per group). 
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Figure 5 
Figure 5: Rgs1 reduces Ang II activation of pErk1/2 signalling in VSMCs. (A) 
Rgs1 transfected VSMCs have reduced pErk1/2 activation following 1 μM Ang II 
stimulation over 30 minutes but not (B) pJNK and (C) pp38 activation (**P < 0.01; 
n = 4 technical replicates, 2 independent experiments).  
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Supplementary Figure 1 
Supplementary Figure 1: Flow cytometric analysis of FLAG intracellular 
expression. MOVAS cells were transfected with an empty vector control plasmid 
or FLAG tag Rgs1 plasmid and 48 hours later, intracellular staining using an anti-
FLAG-FITC antibody was performed. The grey curve represents the empty vector 
control and the green curve represents the fluorescent intensity of the FLAG-FITC 
positive population. The population of Rgs1 transfected cells was 72 % FLAG 
positive at this time point.  
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